Enhancement of chemo-sensitivity by molecular-targeting drugs in gemcitabine-resistant advanced bladder cancer.
Project/Area Number |
20791108
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Urology
|
Research Institution | Kobe University |
Principal Investigator |
MURAMAKI Mototugu Kobe University, 医学部附属病院, 助教 (10448178)
|
Project Period (FY) |
2008 – 2009
|
Project Status |
Completed (Fiscal Year 2009)
|
Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 膀胱癌 / ジェムシタビン抵抗性 / 分子標的薬 / ジェムシタビン / 抗癌剤耐性 / 分子標的治療 / アポトーシス / in vivo study / Clusterin |
Research Abstract |
Clusterin plays significant role in the acquisition of chemo-resistant phenotype in bladder cancer cells and the inactication of Clusterin using OGX-011 combined with chemotherapeutic agent could be an attractive approach for advanced bladder cancer through the enhancement of chemo-sensitivity.
|
Report
(3 results)
Research Products
(3 results)